Survey of Ophthalmology
Volume 45 , Pages S361-S368 , May 2001

Six-Month Comparison of Bimatoprost Once-Daily and Twice-Daily with Timolol Twice-Daily in Patients with Elevated Intraocular Pressure

  • Mark Sherwood, MD

      Affiliations

    • Department of Ophthalmology, University of Florida College of Medicine, Gainesville, FL USA
    • Corresponding Author InformationReprint address: Mark Sherwood, MD, Deptartment of Ophthalmology, University of Florida College of Medicine, Box 100284, 1600 SW Archer Rd., Gainesville, FL 32610-0284.
    • ,
  • James Brandt, MD

      Affiliations

    • Department of Ophthalmology, University of California, Davis, CA, USA
    • ,
  • for the Bimatoprost Study Groups 1 and 2

References 

  1. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126:487–497
  2. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995;102:1743–1752
  3. Asrani S, Zeimer R, Wilensky J, et al.  Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9:134–142
  4. Brandt JD, VanDenburgh AM, Chen K: Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology, In press
  5. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma (a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group). Ophthalmology. 1996;103:138–147
  6. Epstein DL, Krug JH, Hertzmark E, et al.  A long-term clinical trial of timolol therapy versus no treatment in the management of glaucoma suspects. Ophthalmology. 1989;96:1460–1467
  7. Kass MA, Gordon MO, Hoff MR, et al.  Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals. A randomized, double-masked, long-term clinical trial. Arch Ophthalmol. 1989;107:1590–1598
  8. Krauss AH-P, Chen J, Andrews SW. The ocular pharmacology and bioavailability of AGN 192024 (Lumigan™), a novel ocular hypotensive agent. Invest Ophthalmol Vis Sci. 2001;42:S832;[abstract]
  9. Mao LK, Stewart WC, Shields MB. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol. 1991;111:51–55
  10. Morikawa T, Yoshida M. A useful testing strategy in phase III trials (combined test of superiority and test of equivalence). J Biopharm Stat. 1995;5:297–306
  11. Panarello SM, Priolo E, Vittone P. Pediatric ultrasound (a personal experience during the period 1991–1994). Ophthalmologica. 1998;212(Suppl 1):115–117
  12. Singh K, Spaeth G, Zimmerman T, Minckler D. Target pressure—glaucomatologists holey grail. Ophthalmology. 2000;107:629–630
  13. VanDenburgh AM, Laibovitz RA, Felix C. A one-month dose-response study of AGN 192024, a novel antiglaucoma agent, in patients with elevated intraocular pressure. Invest Ophthalmol Vis Sci. 1999;40:S830;[abstract]
  14. Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology. 1996;103:126–137
  15. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol. 1997;41(Suppl 2):S129–S138
  16. Zeimer RC, Wilensky JT, Gieser DK. Presence and rapid decline of early morning intraocular pressure peaks in glaucoma patients. Ophthalmology. 1990;97:547–550
  17. Zeyen T. Target pressures in glaucoma. Bull Soc Belge Ophtalmol. 1999;274:61–65

PII: S0039-6257(01)00219-3

Survey of Ophthalmology
Volume 45 , Pages S361-S368 , May 2001

Article Tools

* Image Usage & Resolution